- The report contains detailed information about BioCancell Therapeutics, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for BioCancell Therapeutics, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The BioCancell Therapeutics, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes BioCancell Therapeutics, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of BioCancell Therapeutics, Inc. business.
About BioCancell Therapeutics, Inc.
BioCancell Therapeutics Inc., a clinical development-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for treating cancer-related diseases.
The company is focused on developing its prospective drug, BC-819. The detection of expression of the H19 gene is the prerequisite for the use of its potential therapy. It has developed BC-819, which is a double stranded DNA plasmid construct that incorporates the gene for diphtheria toxin (DTA) under the regulation of the H19 promoter sequence. BC-819 has also demonstrated potential with respect to combination therapy. Pursuant to an agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (Yissum), Yissum has granted to the company a worldwide license for the use, development, and commercialization of the H19 gene in consideration. The company completed Phase I/IIa trials of its therapy BC-819 designed for use in patients suffering from bladder carcinoma. Polyplus-transfection SA is the supplier of the component polyethylenimine (PEI) which is used to improve its prospective drug BC-819s ability to penetrate cancerous cells in the bladder.
The company's other research and development activities that are in the preliminary stage of laboratory research include the following:
BC-820: BC-820 is a potential therapeutic product that activates both the synthesis of DTA and the protein Tumor Necrosis Factor (TNF) of the cytokine family. BC-820 penetrates cancerous cells expressing the H19 gene and activates the synthesis of DTA and TNF in a targeted manner.
BC-821: BC-821 is a potential therapeutic product that penetrates cancerous cells and activates the synthesis of DTA only in cells expressing the P4 promoter of the target gene IGF2, which like the H19 target gene is expressed only in cancerous cells and not in non-cancerous cells.
BC-822: This potential therapeutic product seeks to suppress the growth of cancerous cells by re-sequencing a cancer cells RNA by way of inserting a small interfering Ribonucleic Acid (siRNA) sequence that prevents the expression of the H19 gene.
BioCancell Therapeutics Inc. was founded in 2004.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. BIOCANCELL THERAPEUTICS, INC. COMPANY PROFILE
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. BIOCANCELL THERAPEUTICS, INC. BUSINESS OVERVIEW
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. BIOCANCELL THERAPEUTICS, INC. SWOT ANALYSIS
4. BIOCANCELL THERAPEUTICS, INC. FINANCIAL ANALYSIS
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. BIOCANCELL THERAPEUTICS, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. BioCancell Therapeutics, Inc. Direct Competitors
5.2. Comparison of BioCancell Therapeutics, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of BioCancell Therapeutics, Inc. and Direct Competitors Stock Charts
5.4. BioCancell Therapeutics, Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. BioCancell Therapeutics, Inc. Industry Position Analysis
6. BIOCANCELL THERAPEUTICS, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. BIOCANCELL THERAPEUTICS, INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. BIOCANCELL THERAPEUTICS, INC. ENHANCED SWOT ANALYSIS2
9. ISRAEL PESTEL ANALYSIS2
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. BIOCANCELL THERAPEUTICS, INC. IFE, EFE, IE MATRICES2
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. BIOCANCELL THERAPEUTICS, INC. PORTER FIVE FORCES ANALYSIS2
12. BIOCANCELL THERAPEUTICS, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
BioCancell Therapeutics, Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
BioCancell Therapeutics, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
BioCancell Therapeutics, Inc. Major Shareholders
BioCancell Therapeutics, Inc. History
BioCancell Therapeutics, Inc. Products
Revenues by Segment
Revenues by Region
BioCancell Therapeutics, Inc. Offices and Representations
BioCancell Therapeutics, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
BioCancell Therapeutics, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
BioCancell Therapeutics, Inc. Capital Market Snapshot
BioCancell Therapeutics, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
BioCancell Therapeutics, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
BioCancell Therapeutics, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
BioCancell Therapeutics, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
BioCancell Therapeutics, Inc. 1-year Stock Charts
BioCancell Therapeutics, Inc. 5-year Stock Charts
BioCancell Therapeutics, Inc. vs. Main Indexes 1-year Stock Chart
BioCancell Therapeutics, Inc. vs. Direct Competitors 1-year Stock Charts
BioCancell Therapeutics, Inc. Article Density Chart
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Key Factors Examined by PESTEL Analysis:
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
Porter Five Forces Analysis
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
- Costly to imitate?
- Organized properly?